Therefore, it would be necessary to confirm that HMGA1 could predict tumor aggressiveness and also guide treatment decisions by measuring the protein levels and analyzing the subcellular localization of HMGA1 in the primary tumors of a large cohort of TNBC patients with and without metastatic involvement. Here, HMGA1 is linked to neoplasm.